Hutchison China MediTech Limited (NASDAQ:HCM) was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Friday.

Separately, Canaccord Genuity set a $30.00 target price on shares of Hutchison China MediTech Limited and gave the stock a “buy” rating in a research report on Monday, July 31st.

Shares of Hutchison China MediTech Limited (NASDAQ HCM) opened at 30.31 on Friday. The stock has a 50 day moving average of $27.41 and a 200-day moving average of $27.41. Hutchison China MediTech Limited has a 1-year low of $10.61 and a 1-year high of $32.03. The stock has a market capitalization of $3.68 billion, a P/E ratio of 285.94 and a beta of -1.89.

COPYRIGHT VIOLATION WARNING: “Hutchison China MediTech Limited (HCM) Stock Rating Upgraded by BidaskClub” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another publication, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this article can be read at https://www.thecerbatgem.com/2017/10/13/hutchison-china-meditech-limited-hcm-stock-rating-upgraded-by-bidaskclub-2.html.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. The Manufacturers Life Insurance Company boosted its position in shares of Hutchison China MediTech Limited by 7.7% in the second quarter. The Manufacturers Life Insurance Company now owns 103,799 shares of the company’s stock worth $2,420,000 after acquiring an additional 7,400 shares during the last quarter. Baillie Gifford & Co. boosted its position in shares of Hutchison China MediTech Limited by 6.1% in the second quarter. Baillie Gifford & Co. now owns 167,547 shares of the company’s stock worth $3,905,000 after acquiring an additional 9,655 shares during the last quarter. JPMorgan Chase & Co. acquired a new stake in shares of Hutchison China MediTech Limited in the second quarter worth approximately $5,102,000. Renaissance Technologies LLC acquired a new stake in shares of Hutchison China MediTech Limited in the first quarter worth approximately $618,000. Finally, Wellington Management Group LLP boosted its position in shares of Hutchison China MediTech Limited by 7.4% in the first quarter. Wellington Management Group LLP now owns 510,826 shares of the company’s stock worth $10,190,000 after acquiring an additional 35,053 shares during the last quarter. 4.06% of the stock is currently owned by institutional investors and hedge funds.

About Hutchison China MediTech Limited

Hutchison China MediTech Limited (Chi-Med) is a China-based, globally-focused healthcare group. The Company researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market.

Receive News & Stock Ratings for Hutchison China MediTech Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hutchison China MediTech Limited and related stocks with our FREE daily email newsletter.